Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Relapsed or Refractory Hematological Malignancies”

278 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 278 results

Early research (Phase 1)Not Yet RecruitingNCT07113496
What this trial is testing

RN1201injection for Relapsed/Refractory CD19+/BCMA+ Hematologic Malignancies

Who this might be right for
Relapsed or Refractory B-cell Hematologic MalignanciesB-cell Acute Lymphoblastic Leukemia (B-ALL)Multiple Myeloma (MM)+3 more
The First Affiliated Hospital with Nanjing Medical University 27
Not applicableUnknownNCT00295997
What this trial is testing

Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer, Metastatic Kidney Cancer, or Aplastic Anemia

Who this might be right for
Chronic Myeloproliferative DisordersKidney CancerLeukemia+4 more
University of California, San Francisco 35
Testing effectiveness (Phase 2)Study completedNCT02061761
What this trial is testing

Evaluate the Safety, Tolerability, and Efficacy of Relatlimab in Relapsed or Refractory B-Cell Malignancies

Who this might be right for
Hematologic Neoplasms
Bristol-Myers Squibb 106
Testing effectiveness (Phase 2)Ended earlyNCT00861965
What this trial is testing

Bioengineered Allogeneic Immune Cells (AlloStim) Not Requiring HLA Donor Match for Blood Cancers

Who this might be right for
Advanced or Refractory Leukemia, Lymphoma, Multiple Myeloma
Mirror Biologics, Inc. 2
Testing effectiveness (Phase 2)Looking for participantsNCT05745714
What this trial is testing

HEM-iSMART-C: Ruxolitinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients With Relapsed or Refractory Hematological Malignancies

Who this might be right for
Acute Lymphoblastic Leukemia, in RelapseLymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) RecurrentLymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Recurrent+2 more
Princess Maxima Center for Pediatric Oncology
Large-scale testing (Phase 3)Study completedNCT03859427
What this trial is testing

A Study Comparing Once-weekly vs Twice-weekly Carfilzomib in Combination With Lenalidomide and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma

Who this might be right for
Relapsed or Refractory Multiple Myeloma
Amgen 454
Early research (Phase 1)Active Not RecruitingNCT04623944
What this trial is testing

NKX101, Intravenous Allogeneic CAR NK Cells, in Adults With AML or MDS

Who this might be right for
Relapsed/Refractory AMLAML, AdultMDS+1 more
Nkarta, Inc. 61
Early research (Phase 1)Study completedNCT01871675
What this trial is testing

Study of IPI-145 in Combination With Rituximab or Bendamustine/Rituximab in Hematologic Malignancies

Who this might be right for
LymphomaChronic Lymphocytic LeukemiaNon-Hodgkin Lymphoma+1 more
SCRI Development Innovations, LLC 48
Not applicableStudy completedNCT00053157
What this trial is testing

Sargramostim in Reducing Graft-Versus-Host Disease in Patients Who Are Undergoing Donor Stem Cell Transplantation for Hematologic Cancer or Aplastic Anemia

Who this might be right for
Chronic Myeloproliferative DisordersGraft Versus Host DiseaseLeukemia+3 more
Roswell Park Cancer Institute 10
Early research (Phase 1)Ended earlyNCT06343376
What this trial is testing

Genetically Engineered Cells (EGFRt/19-28z/IL-12 CAR T Cells) for the Treatment of Relapsed or Refractory CD19+ Hematologic Malignancies

Who this might be right for
Recurrent Chronic Lymphocytic LeukemiaRecurrent Diffuse Large B-Cell LymphomaRecurrent Follicular Lymphoma+11 more
Roswell Park Cancer Institute 1
Testing effectiveness (Phase 2)Ended earlyNCT02259348
What this trial is testing

Repeat Transplantation for Relapsed or Refractory Hematologic Malignancies Following Prior Transplantation

Who this might be right for
Acute Lymphoblastic Leukemia (ALL)Acute Myeloid Leukemia (AML)Myeloid Sarcoma+4 more
St. Jude Children's Research Hospital 12
Very early researchUnknownNCT06393335
What this trial is testing

Safety and Efficacy of Metabolically Armed CD19 CAR-T Cells (Meta10-19) in the Treatment of Relapsed and/or Refractory CD19-positive B Cell Hematological Malignancies Clinical Research

Who this might be right for
Acute Lymphoblastic LeukemiaNon-hodgkin Lymphoma
The Children's Hospital of Zhejiang University School of Medicine 36
Early research (Phase 1)Looking for participantsNCT05362773
What this trial is testing

MGD024 in Patients With Relapsed or Refractory Hematologic Malignancies

Who this might be right for
Leukemia, Acute MyeloidMyelodysplastic SyndromesClassical Hodgkin Lymphoma+5 more
MacroGenics 130
Early research (Phase 1)UnknownNCT04599556
What this trial is testing

Clinical Trial for the Safety and Efficacy of Anti-CD7 CAR-T Cell Therapy for Patients With Relapsed or Refractory CD7 Positive Hematological Malignancy

Who this might be right for
CD7+ Acute LeukemiaCD7+ Lymphoma
Zhejiang University 81
Testing effectiveness (Phase 2)Ended earlyNCT01621477
What this trial is testing

T-Cell Replete Haploidentical Donor Hematopoietic Stem Cell Plus Natural Killer (NK) Cell Transplantation in Patients With Hematologic Malignancies Relapsed or Refractory Despite Previous Allogeneic Transplant

Who this might be right for
Acute Lymphoblastic LeukemiaAcute Myelocytic LeukemiaChronic Myelocytic Leukemia+4 more
St. Jude Children's Research Hospital 34
Testing effectiveness (Phase 2)Study completedNCT01592370
What this trial is testing

An Investigational Immuno-Therapy Study to Determine the Safety and Effectiveness of Nivolumab and Daratumumab in Patients With Multiple Myeloma

Who this might be right for
Non-Hodgkin's LymphomaHodgkin LymphomaMultiple Myeloma
Bristol-Myers Squibb 320
Early research (Phase 1)Active Not RecruitingNCT06325748
What this trial is testing

SENTI-202: Off-the-shelf Logic Gated CAR NK Cell Therapy in Adults With CD33 and/or FLT3 Blood Cancers Including AML/MDS

Who this might be right for
AML/MDSCD33 Expressing Hematological MalignanciesFLT3 Expressing Hematological Malignancies
Senti Biosciences 21
Early research (Phase 1)Looking for participantsNCT05735184
What this trial is testing

Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML

Who this might be right for
Acute Myeloid LeukemiaMixed Lineage Leukemia Gene MutationRefractory AML+7 more
Kura Oncology, Inc. 420
Large-scale testing (Phase 3)Study completedNCT00003687
What this trial is testing

Treatment for Chronic Pain in Patients With Advanced Cancer

Who this might be right for
Chronic Myeloproliferative DisordersLeukemiaLymphoma+6 more
NCIC Clinical Trials Group 87
Early research (Phase 1)UnknownNCT05445765
What this trial is testing

Anti-CD33 CAR-T Cells for the Treatment of Relapsed/Refractory CD33+ Acute Myeloid Leukemia

Who this might be right for
Relapsed and/or Refractory Acute Myeloid LeukemiaHigh Risk Hematologic Malignancies
iCell Gene Therapeutics 10
Load More Results
26